Currently out of the existing stock ratings of Thomas Smith, 95 are a BUY (83.33%), 19 are a HOLD (16.67%).

Thomas Smith

Work Performance Price Targets & Ratings Chart

Analyst Thomas Smith, carries an average stock price target met ratio of 41.45% that have a potential upside of 31.84% achieved within 169 days. Previously, Thomas Smith worked at LEERINK.

Thomas Smith’s has documented 214 price targets and ratings displayed on 43 stocks. The coverage was on Healthcare, Industrials, Financial Services, Technology, Consumer Defensive sectors.

Most recent stock forecast was given on CLDX, Celldex Therapeutics at 22-Sep-2026.

Wall Street Analyst Thomas Smith

Analyst best performing recommendations are on AXLA (AXCELLA HEALTH).
The best stock recommendation documented was for AXLA (AXCELLA HEALTH) at 12/15/2022. The price target of $6 was fulfilled within 1 day with a profit of $4.98 (45.36%) receiving and performance score of 453.55.

Average potential price target upside

ALLK Allakos IMVT Immunovant KROS Keros Therapeutics AXLA Axcella Health CLDX Celldex Therapeutics EQ Equillium CNTB Connect Biopharma Holdings Ltd DICE Dice Molecules Holdings LLC ELDN Eledon Pharmaceuticals ETNB 89bio GLTO Galecto LABP Landos Biopharma PRTC PureTech Health PLC RXDX Prometheus Biosciences ARGX argenx NV ADR ICPT Intercept Pharmaceuticals IMUX Immunic PRVB Provention Bio CBAY Cymabay Therapeu ETN Eaton PLC MORF Morphic PLRX Pliant Therapeutics VECT VectivBio Holding AG VRDN Viridian Therapeutics RAPT RAPT Therapeutics ALPN Alpine Immune Sciences IRON Disc Medicine QTTB Q32 Bio ABVX Abivax SA American Depositary Shares ALL The Allstate ALMS Alumis Common Stock ARRY Array Technologies GL Globe Life MDGL Madrigal Pharmaceuticals MO Altria Group TRML Tourmaline Bio TRVI Trevi Therapeutics GNFT Genfit MLTX MoonLake Immunotherapeutics MNKD MannKind Corp SABS SAB Biotherapeutics SGMT Sagimet Biosciences Series A Common Stock ACRS Aclaris Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$3

$1.79 (147.93%)

$3

2 years 11 days ago
(26-Sep-2024)

0/4 (0%)

$2.42 (417.24%)

Hold

$7

2 years 3 months 17 days ago
(20-Jun-2024)

1/3 (33.33%)

$0.45 (6.87%)

57

Sell

$1

$-0.21 (-17.36%)

$1.5

2 years 8 months 20 days ago
(17-Jan-2024)

6/6 (100%)

$-0.02 (-1.96%)

278

Buy

2 years 9 months 19 days ago
(18-Dec-2023)

1/1 (100%)

$32.69 (83.16%)

358

Buy

$9

$7.79 (643.80%)

3 years 4 months 26 days ago
(11-May-2023)

2/4 (50%)

$4.84 (116.35%)

178

Show more analysts

Please expand the browser size to see the chart

Which stock is Thomas Smith most bullish on?

Potential upside of $56.35 has been obtained for CLDX (CELLDEX THERAPEUTICS)

Which stock is Thomas Smith most reserved on?

Potential downside of $4.59 has been obtained for EQ (EQUILLIUM)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?